Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2001 1
2004 1
2006 1
2008 1
2010 2
2014 3
2016 2
2019 2
2020 3
2021 1
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-beta-Blocking R-Enantiomer Carvedilol.
Seo K, Yamamoto Y, Kirillova A, Kawana M, Yadav S, Huang Y, Wang Q, Lane KV, Pruitt BL, Perez MV, Bernstein D, Wu JC, Wheeler MT, Parikh VN, Ashley EA. Seo K, et al. Among authors: ashley ea. Circulation. 2023 Nov 21;148(21):1691-1704. doi: 10.1161/CIRCULATIONAHA.123.065017. Epub 2023 Oct 18. Circulation. 2023. PMID: 37850394
Clinically available carvedilol is a racemic mixture, and the R-enantiomer, devoid of beta-blocking effect, retains the ability to inhibit both alpha(1)-receptor and RyR2, thereby suppressing contractile function and arrhythmias without lowering heart rate and cardiac outp …
Clinically available carvedilol is a racemic mixture, and the R-enantiomer, devoid of beta-blocking effect, retains the ability to in …
Primaquine: the risks and the benefits.
Ashley EA, Recht J, White NJ. Ashley EA, et al. Malar J. 2014 Nov 3;13:418. doi: 10.1186/1475-2875-13-418. Malar J. 2014. PMID: 25363455 Free PMC article. Review.
Review of dose-response relationships and clinical trials of primaquine in G6PD deficiency suggests that the currently recommended WHO single low dose (0.25 mg base/kg) to block falciparum malaria transmission confers a very low risk of haemolytic toxicity....
Review of dose-response relationships and clinical trials of primaquine in G6PD deficiency suggests that the currently recommended WHO singl …
Scalable Preparation of 4,4-Disubstituted Six-Membered Cyclic Sulfones.
Hugelshofer CL, Bao J, Du J, Ashley E, Yu W, Ji T, Hu B, Liu D, Rondla R, Karampuri S, Sharma V, Ethiraj K, Lim YH. Hugelshofer CL, et al. Among authors: ashley e. Org Lett. 2021 Feb 5;23(3):943-947. doi: 10.1021/acs.orglett.0c04141. Epub 2021 Jan 8. Org Lett. 2021. PMID: 33417467
We provide an account of synthetic strategies aimed at the efficient preparation of 4-amino-4-methyltetrahydro-2H-thiopyran 1,1-dioxide (3), an important cyclic sulfone building block for medicinal chemistry. A practical and scalable protocol has been developed that readil …
We provide an account of synthetic strategies aimed at the efficient preparation of 4-amino-4-methyltetrahydro-2H-thiopyran 1,1-dioxide (3), …
Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria.
White NJ, Ashley EA, Recht J, Delves MJ, Ruecker A, Smithuis FM, Eziefula AC, Bousema T, Drakeley C, Chotivanich K, Imwong M, Pukrittayakamee S, Prachumsri J, Chu C, Andolina C, Bancone G, Hien TT, Mayxay M, Taylor WR, von Seidlein L, Price RN, Barnes KI, Djimdé A, ter Kuile F, Gosling R, Chen I, Dhorda MJ, Stepniewska K, Guérin P, Woodrow CJ, Dondorp AM, Day NP, Nosten FH. White NJ, et al. Among authors: ashley ea. Malar J. 2014 Dec 9;13:483. doi: 10.1186/1475-2875-13-483. Malar J. 2014. PMID: 25486998 Free PMC article. Review.
Indirect clinical measures assessing anti-malarial drug transmission-blocking activity in falciparum malaria include measurement of the duration of gametocytaemia, the rate of gametocyte clearance or the area under the gametocytaemia-time curve (AUC). ...In choosing doses …
Indirect clinical measures assessing anti-malarial drug transmission-blocking activity in falciparum malaria include measurement of t …
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
Schilling WHK, Jittamala P, Watson JA, Boyd S, Luvira V, Siripoon T, Ngamprasertchai T, Batty EM, Cruz C, Callery JJ, Singh S, Saroj M, Kruabkontho V, Ngernseng T, Tanglakmankhong N, Tubprasert J, Abdad MY, Madmanee W, Kouhathong J, Suwannasin K, Pagornrat W, Piaraksa N, Hanboonkunupakarn P, Hanboonkunupakarn B, Poovorawan K, Potaporn M, Srisubat A, Loharjun B, Taylor WRJ, Chotivanich V, Chotivanich K, Imwong M, Pukrittayakamee S, Dondorp AM, Day NPJ, Teixeira MM, Piyaphanee W, Phumratanaprapin W, White NJ; PLATCOV Collaborative Group. Schilling WHK, et al. Lancet Infect Dis. 2024 Jan;24(1):36-45. doi: 10.1016/S1473-3099(23)00493-0. Epub 2023 Sep 28. Lancet Infect Dis. 2024. PMID: 37778363 Free PMC article. Clinical Trial.
We recruited low-risk adult patients aged 18-50 years with early symptomatic COVID-19 (<4 days of symptoms). Eligible patients were randomly assigned using block randomisation via a centralised web app to one of seven treatment groups: molnupiravir, ritonavir-boosted ni …
We recruited low-risk adult patients aged 18-50 years with early symptomatic COVID-19 (<4 days of symptoms). Eligible patients were rando …
Brugada syndrome and anesthetic management.
Cordery R, Lambiase P, Lowe M, Ashley E. Cordery R, et al. Among authors: ashley e. J Cardiothorac Vasc Anesth. 2006 Jun;20(3):407-13. doi: 10.1053/j.jvca.2006.02.005. Epub 2006 May 4. J Cardiothorac Vasc Anesth. 2006. PMID: 16750748 Review. No abstract available.
COSMOS: a platform for real-time morphology-based, label-free cell sorting using deep learning.
Salek M, Li N, Chou HP, Saini K, Jovic A, Jacobs KB, Johnson C, Lu V, Lee EJ, Chang C, Nguyen P, Mei J, Pant KP, Wong-Thai AY, Smith QF, Huang S, Chow R, Cruz J, Walker J, Chan B, Musci TJ, Ashley EA, Masaeli MM. Salek M, et al. Among authors: ashley ea. Commun Biol. 2023 Sep 22;6(1):971. doi: 10.1038/s42003-023-05325-9. Commun Biol. 2023. PMID: 37740030 Free PMC article.
Cells are the singular building blocks of life, and a comprehensive understanding of morphology, among other properties, is crucial to the assessment of underlying heterogeneity. ...
Cells are the singular building blocks of life, and a comprehensive understanding of morphology, among other properties, is crucial t …
Classifying Drugs by their Arrhythmogenic Risk Using Machine Learning.
Sahli-Costabal F, Seo K, Ashley E, Kuhl E. Sahli-Costabal F, et al. Among authors: ashley e. Biophys J. 2020 Mar 10;118(5):1165-1176. doi: 10.1016/j.bpj.2020.01.012. Epub 2020 Jan 22. Biophys J. 2020. PMID: 32023435 Free PMC article.
We demonstrate that our classifier correctly identifies the risk categories of 22 common drugs exclusively on the basis of their concentrations at 50% current block. Our new risk assessment tool explains under which conditions blocking the L-type calcium current can …
We demonstrate that our classifier correctly identifies the risk categories of 22 common drugs exclusively on the basis of their concentrati …
22 results